Lucas Antônio dos Santos Barbosa

Prof. Lucas Antônio dos Santos Barbosa

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BABassel Almarie
Bassel Almarie
LGLuis Fernando Gonzalez-Gonzalez
Luis Fernando Gonzalez-Gonzalez
Lucas Antônio dos Santos BarbosaLucas Antônio dos Santos Barbosa
Lucas Antônio dos Santos Barbosa
ALAmelie Lutz
Amelie Lutz
UGUlrich Grosse
Ulrich Grosse
Felipe FregniFelipe Fregni
Felipe Fregni
Background: The US Food and Drug Administration (FDA) authorized over 690 machine learning (ML)-enabled medical devices between 1995 and 2023. In 2024, new guidance enabled the inclusion of Predetermined Change Control Plans (PCCPs), raising expectations for transparency, equity, and safety under the Good Machine Learning Practice (GMLP) framework. Objective: The objective was to assess regulatory pathways, predicate lineage, demographic transparency, performance reporting, and PCCP uptake among ML-enabled devices approved by the FDA in 2024. Methods: We conducted a cross-sectional analysis of all FDA-authorized ML-enabled devices in 2024. Data extracted from FDA summaries included regulatory pathway, predicate genealogy, performance metrics, demographic disclosures, PCCPs, and cybersecurity statements. Descriptive and nonparametric statistics were used. Results: The FDA authorized 168 ML-enabled Class II devices in 2024. Most (94.6%) were cleared via 510(k); 5.4% were cleared via De Novo. Radiology dominated (74.4%), followed by cardiovascular (6.5%) and neurology (6.0%). Non-US sponsors accounted for 57.7% of clearances. Among 159 510(k) devices, 97.5% cited an identifiable predicate; the median predicate age was 2.2 years (IQR 1.2–4.1), and 64.5% ML-enabled. Predicate reuse remained uncommon (9.9%). Median review time was 162 days (151 days for 510(k) vs. 372 days De Novo; p < 0.001). A total of 49 devices (29.2%) reported both sensitivity and specificity; 15.5% provided demographic data. PCCPs appeared in 16.7% of summaries, and cybersecurity considerations appeared in 54.2%. Conclusions: While 2024 marked a record year for ML-enabled device approvals and internationalization, uptake of PCCPs and transparent performance and demographic reporting remained limited. Policy efforts to standardize disclosures and strengthen post market oversight are critical for realizing the promises of GMLP.

31 August 2022 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
EDEslen Delanogare
Eslen Delanogare
SBSebastien Bullich
Sebastien Bullich
Lucas Antônio dos Santos BarbosaLucas Antônio dos Santos Barbosa
Lucas Antônio dos Santos Barbosa
WBWellinghton de Medeiros Barros
Wellinghton de Medeiros Barros
SBSara Pereira Braga
Sara Pereira Braga
EMEduardo Luiz Gasnhar Moreira
Eduardo Luiz Gasnhar Moreira

18 November 2022 in Addiction Biology
Verified
Journal Article
Closed access
Lucas Antônio dos Santos BarbosaLucas Antônio dos Santos Barbosa
Lucas Antônio dos Santos Barbosa
RDRafael Cypriano Dutra
Rafael Cypriano Dutra
EMEduardo Luiz Gasnhar Moreira
Eduardo Luiz Gasnhar Moreira
CCCristiane Ribeiro de Carvalho
Cristiane Ribeiro de Carvalho

24 September 2025 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
Lucas Antônio dos Santos BarbosaLucas Antônio dos Santos Barbosa
Lucas Antônio dos Santos Barbosa
LALucas Antônio
Lucas Antônio
BABassel Almarie
Bassel Almarie
EMEduardo Luiz Gasnhar Moreira
Eduardo Luiz Gasnhar Moreira

26 August 2026 in World Patent Information
Verified
Journal Article
Open access
Lucas Antônio dos Santos BarbosaLucas Antônio dos Santos Barbosa
Lucas Antônio dos Santos Barbosa
BABassel Almarie
Bassel Almarie
GTGuilherme Toledo
Guilherme Toledo
EMEduardo Luiz Gasnhar Moreira
Eduardo Luiz Gasnhar Moreira